---
title: "CICC: Raises WuXi Biologics target price to HKD 19.09, maintains \"Outperform\" rating"
description: "CICC raised the target price for WuXi Biologics to HKD 19.09, maintaining an \"outperform\" rating. WuXi Biologics reached an agreement with Merck, under which Merck will acquire WuXi Biologics' vaccine"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/224161441.md"
published_at: "2025-01-07T08:13:23.000Z"
---

# CICC: Raises WuXi Biologics target price to HKD 19.09, maintains "Outperform" rating

> CICC raised the target price for WuXi Biologics to HKD 19.09, maintaining an "outperform" rating. WuXi Biologics reached an agreement with Merck, under which Merck will acquire WuXi Biologics' vaccine factory in Ireland for approximately USD 500 million. CICC believes this transaction will enhance WuXi Biologics' asset efficiency and profit margins, and improve liquidity to support capacity expansion and stock buybacks. The earnings forecasts for 2024 and 2025 remain unchanged, with the introduction of the 2026 earnings forecast at CNY 4.693 billion

CICC published a report stating that WuXi Biologics announced an agreement with Merck for its vaccine factory in Ireland, where Merck will acquire WuXi Biologics' vaccine facility in Ireland, with a total transaction amount of approximately USD 500 million. The company expects this transaction to meet customary closing conditions in the first half of the year. CICC believes that through this transaction, WuXi Biologics can further enhance asset efficiency and profit margins, focusing on the Suzhou base to provide more clients with vaccine CDMO services, while also benefiting the company's liquidity for capacity expansion and stock repurchase. It also believes that this transaction demonstrates the company's ability to build and operate world-leading complex vaccine production facilities according to the international standards of global vaccine giants. The firm maintains its earnings forecasts for WuXi Biologics for 2024 and 2025, and introduces its first earnings forecast for 2026 at CNY 4.693 billion. The firm maintains an "outperform industry" rating and raises its target price by 15% to HKD 19.09, considering the systematic upward adjustment in the pharmaceutical sector

### Related Stocks

- [WXXWY.US - WuXi Biologics](https://longbridge.com/en/quote/WXXWY.US.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [06185.HK - CANSINOBIO](https://longbridge.com/en/quote/06185.HK.md)
- [603392.CN - Wantai Biological](https://longbridge.com/en/quote/603392.CN.md)
- [300142.CN - WALVAX](https://longbridge.com/en/quote/300142.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)
- [03908.HK - CICC](https://longbridge.com/en/quote/03908.HK.md)
- [300122.CN - ZHIFEI-BIOL](https://longbridge.com/en/quote/300122.CN.md)
- [300601.CN - BioKangtai](https://longbridge.com/en/quote/300601.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 15:02 ETDisrupting Chronic Cough: Julian Circo Brings AI to the World's Oldest Symptom | Julian Circo, Co-Founder of Hyfe, discusses on the Disruption Interruption podcast how his company is revolutionizing re | [Link](https://longbridge.com/en/news/276373106.md) |
| Labcorp Holdings Stock: Is Wall Street Bullish or Bearish? | Labcorp Holdings Stock: Is Wall Street Bullish or Bearish? | [Link](https://longbridge.com/en/news/276331774.md) |
| U2 releases song 'American Obituary' honoring Renee Good | U2 has released a song titled "American Obituary" as a tribute to Renee Good, a mother killed by an ICE officer in Minne | [Link](https://longbridge.com/en/news/276275369.md) |
| Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes \| DASTY Stock News | Dassault Systèmes announces that Pascal Daloz has been appointed as both CEO and Chairman of the Board, effective Februa | [Link](https://longbridge.com/en/news/276518971.md) |
| Demystifying Garmin: Insights From 4 Analyst Reviews | Garmin (NYSE:GRMN) received mixed ratings from 4 analysts over the past three months, with an average 12-month price tar | [Link](https://longbridge.com/en/news/276365030.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.